IN8bio reports Q2 2023 net loss of $7.7M, cash $17.0M; positive INB-200 Phase 1 data

IN8BIO, INC.

2023-Q2 EPS reported -$0.57

Net loss $7.7M ($0.27/sh) vs $7.2M ($0.38/sh) in Q2 2022; R&D expense $4.1M, G&A $3.6M.
Cash $17.0M as of June 30, 2023, up from $10.9M on March 31, 2023.
INB-200 Phase 1 data: 100% of treated GBM patients (n=8) exceeded median PFS; enrollment completion expected in 2023.
INB-400 Phase 2 trial in GBM on track to initiate enrollment in H2 2023; primary endpoint overall survival.
R&D day scheduled for October 12, 2023 in New York City; preclinical ovarian cancer data presented at ASGCT.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

IN8BIO, INC. reported the quarter ended June 30, 2023 results: net income $7.7 million, EPS $0.27 per basic and diluted common share.

Period: the quarter ended June 30, 2023
Net income: $7.7 million
EPS: $0.27 per basic and diluted common share
Result: reported results

Exact text from the filing

IN8bio, Inc. (Nasdaq: INAB), a leading clinical-stage biopharmaceutical company developing innovative gamma-delta T cell therapies, today announced financial results and operational highlights for the second quarter ended June 30, 2023.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

IN8BIO, INC. filing history →

Source: SEC EDGAR

accession 0000950170-23-041481

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.